Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma-Reference-Cited by-同舟云学术

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma

Published:2019-02-04 Issue:4 Volume:62 Page:2140-2153
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Xiaojing¹^ORCID,Blackaby Wesley²,Allen Vivienne²,Chan Grace Ka Yan¹,Chang Jae H.¹,Chiang Po-Chang¹,Diène Coura²,Drummond Jason¹,Do Steven¹,Fan Eric¹,Harstad Eric B.¹,Hodges Alastair²,Hu Huiyong¹,Jia Wei¹,Kofie William²,Kolesnikov Aleksandr¹,Lyssikatos Joseph P.¹,Ly Justin¹,Matteucci Mizio²,Moffat John G.¹,Munugalavadla Veerendra¹,Murray Jeremy¹^ORCID,Nash David²,Noland Cameron L.¹,Del Rosario Geoff¹,Ross Leanne¹,Rouse Craig²,Sharpe Andrew²,Slaga Dionysos¹,Sun Minghua¹,Tsui Vickie¹,Wallweber Heidi¹,Yu Shang-Fan¹,Ebens Allen J.¹

Affiliation:

1. Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

2. Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom

Funder

Genentech

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01857

Reference53 articles.

1. Multiple Myeloma

2. Multiple myeloma epidemiology and survival: A unique malignancy

3. The start of a new wave: Developments in proteasome inhibition in multiple myeloma